On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
MondayNov 03, 2008 4:23 am

Arena Resources, Inc. (NYSE: (TSX: ARD)

Arena Resources, Inc. (NYSE: ARD), an Oklahoma-based oil and gas exploration, development and production company, has its operations focused on Texas, Oklahoma, Kansas and New Mexico. Since the company’s beginning, experienced management executives have aggressively sought to acquire select properties that provide immediate positive cash flow and development opportunities for the future. So far, the company has made acquisitions representing an estimated 55.4 million BOE's (barrel of oil equivalents) and an estimated $1,982.0 billion* in PV-10 (future net revenues discounted 10%). For further information, visit the Company's web site at www.arenaresourcesinc.com.

Continue Reading

MondayNov 03, 2008 4:22 am

Arcan Resources Ltd. (TSX: ARN CN)

Arcan Resources Ltd. (TSX: ARN CN), a high-growth junior producer, has a balanced portfolio of assets positioned in the Deer Mountain, McLeod and Hamburg areas. The company is approximately 75 percent oil weighted and all oil production is greater than 40º API sweet crude. Arcan is a full cycle exploration company through the drill bit and anticipates adding acquisitions that consolidate holdings or accelerate growth. For further information, visit the Company's web site at www.arcanres.com.

Continue Reading

MondayNov 03, 2008 4:22 am

Nile Therapeutics, Inc. (NASDAQ: NLTX)

Nile Therapeutics, Inc. (NASDAQ: NLTX), a clinical-stage biopharmaceutical company, is focused on developing novel products designed to treat cardiovascular disease. CD-NP, the company’s lead compound, is a chimeric natriuretic peptide that is currently in clinical studies for an initial indication of acute decompensated heart failure. Additionally, the company is also developing CU-NP, a chimeric natriuretic peptide, and 2NTX-99, a small molecule with anti-atherothrombotic and nitric oxide donating properties. For further information, visit the Company's web site at www.nilethera.com.

Continue Reading

MondayNov 03, 2008 4:21 am

NGAS Resources, Inc. (NASDAQ: NGAS)

NGAS Resources, Inc. (NASDAQ: NGAS), an independent exploration and production company, has focused its operations primarily on the Appalachian Basin. The company generates its own geological prospects in this region and has strategically structured its business to achieve capital appreciation through growth in natural gas reserves, production, and cash flow. NGAS has the competitive advantage of acquiring nearby acreage not yet developed. For further information, visit the Company's web site at www.ngas.com.

Continue Reading

MondayNov 03, 2008 4:21 am

New Guinea Gold Corporation (TSX:NGG CN)

New Guinea Gold Corporation (TSX: NGG CN), the premier junior explorer and miner in Papua New Guinea, has direct and indirect interests in twelve properties. With 75,000 + metres of drilling completed, extensive gold or copper-gold-molybdenum mineralization has been discovered at 11 of the properties while the 12th contains widespread and extensive alluvial gold. The company’s Sinivit mine is anticipated to generate cash flow for on-going exploration of other large scale targets. For further information, visit the Company's web site at www.newguineagold.ca.

Continue Reading

MondayNov 03, 2008 4:20 am

Nevsun Resources, Ltd. (AMEX: NSU)

Nevsun Resources, Ltd. (AMEX: NSU), a gold and base metal explorer/developer, is focused on developing mining projects in Africa. Currently, the company is dedicating its efforts to advancing its high grade gold, copper and zinc Bisha Project in Eritrea. A feasibility study for this project was completed in 2006. Nevsun’s mining license covers an area of 16.5 square kilometers (includes the Bisha Main Zone deposit and the Northwest Zone deposit) within a mining agreement area of approximately 39 square kilometers. For further information, visit the Company's web site at www.nevsun.com.

Continue Reading

MondayNov 03, 2008 4:20 am

NeurogesX, Inc. (NASDAQ: NTII)

NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company based in the San Francisco Bay Area, is focused on developing effective treatments that relieve chronic pain and improve quality of life. NGX-4010, the company’s leading product candidate, could possibly revolutionize the treatment of neuropathic pain as a single application may provide months of relief. The product candidate is currently in Phase 3 clinical trials. For further information, visit the Company's web site at www.neurogesx.com

Continue Reading

MondayNov 03, 2008 4:19 am

Arcade Acquisition Corporation (OTC BB: ACDQ)

Arcade Acquisition Corporation (OTC BB: ACDQ) is a private investment partnership that invests in middle-market leveraged buy-out and recapitalization transactions. Arcade gained national recognition for prior investments such as American Cellular Corporation and BoxUSA Inc. Led by their three principals John Chapman, Jonathan Furer and Muhit Rahman, Arcade Acquisition is well-placed for the future. For further information, visit the company website at: www.arcadepartners.com.

Continue Reading

MondayNov 03, 2008 4:19 am

Neurobiological Technologies, Inc. (NASDAQ: NTII)

Neurobiological Technologies, Inc. (NASDAQ: NTII), a biotechnology company, has their focus on acquiring and developing central nervous system (CNS) related drug candidates. The company strategically in-licenses late-stage CNS agents and then pursues regulatory approval and commercialization. Neurobiological’s goal as a company is to develop and market drug candidates in the United States, Europe and Asia while possibly seeking partnerships with pharmaceutical and biotechnology companies. For further information, visit the Company's web site at www.ntii.com.

Continue Reading

MondayNov 03, 2008 4:18 am

Neuralstem, Inc. (AMEX: CUR)

Neuralstem, Inc. (AMEX: CUR), a publicly traded biotherapeutics company, is focused on applying stem cell research and its patented human neural stem cell technology to treat diseases of the central nervous system. The company’s patent-protected technology allows them to produce mature, commercial quantities of neural stem cells that have the capability to control the differentiation of the cells into physiologically relevant human neurons and glia. For further information, visit the Company's web site at www.neuralstem.com.

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered